1. Design, implementation, and first-year outcomes of a value-based drug formulary.

    Journal of managed care & specialty pharmacy 21(4):269 (2015) PMID 25803760

    Value-based insurance design attempts to align drug copayment tier with value rather than cost. Previous implementations of value-based insurance design have lowered copayments for drugs indicated for select "high value" conditions and have found modest improvements in medication adherence. Howe...
  2. Design, implementation, and first-year outcomes of a value-based drug formulary.

    Journal of managed care & specialty pharmacy 21(4):269 (2015) PMID 25803760

    Value-based insurance design attempts to align drug copayment tier with value rather than cost. Previous implementations of value-based insurance design have lowered copayments for drugs indicated for select "high value" conditions and have found modest improvements in medication adherence. Howe...
  3. Association of early imaging for back pain with clinical outcomes in older adults.

    JAMA 313(11):1143 (2015) PMID 25781443

    In contrast to the recommendations for younger adults, many guidelines allow for older adults with back pain to undergo imaging without waiting 4 to 6 weeks. However, early imaging may precipitate interventions that do not improve outcomes. To compare function and pain at the 12-month follow-up ...
  4. Cost-Effectiveness Analysis Alongside Clinical Trials II-An ISPOR Good Research Practices Task Force Report.

    Value in Health 18(2):161 (2015) PMID 25773551

    Clinical trials evaluating medicines, medical devices, and procedures now commonly assess the economic value of these interventions. The growing number of prospective clinical/economic trials reflects both widespread interest in economic information for new technologies and the regulatory and re...
  5. Cost-Effectiveness Analysis Alongside Clinical Trials II-An ISPOR Good Research Practices Task Force Report.

    Value in Health 18(2):161 (2015) PMID 25773551

    Clinical trials evaluating medicines, medical devices, and procedures now commonly assess the economic value of these interventions. The growing number of prospective clinical/economic trials reflects both widespread interest in economic information for new technologies and the regulatory and re...
  6. Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis.

    Value in Health 18(2):173 (2015) PMID 25773552

    To estimate the cost-effectiveness of tocilizumab (TCZ) monotherapy (Mono) versus adalimumab (ADA) Mono from the US payer perspective in patients with rheumatoid arthritis for whom methotrexate is inappropriate. We compared TCZ Mono (8 mg/kg monthly) with ADA Mono (40 mg every other week), using...
  7. Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis.

    Value in Health 18(2):173 (2015) PMID 25773552

    To estimate the cost-effectiveness of tocilizumab (TCZ) monotherapy (Mono) versus adalimumab (ADA) Mono from the US payer perspective in patients with rheumatoid arthritis for whom methotrexate is inappropriate. We compared TCZ Mono (8 mg/kg monthly) with ADA Mono (40 mg every other week), using...
  8. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a national institutes of health pathways to prevention workshop.

    Annals of Internal Medicine 162(4):276 (2015) PMID 25581257

    Increases in prescriptions of opioid medications for chronic pain have been accompanied by increases in opioid overdoses, abuse, and other harms and uncertainty about long-term effectiveness. To evaluate evidence on the effectiveness and harms of long-term (>3 months) opioid therapy for chronic ...
  9. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a national institutes of health pathways to prevention workshop.

    Annals of Internal Medicine 162(4):276 (2015) PMID 25581257

    Increases in prescriptions of opioid medications for chronic pain have been accompanied by increases in opioid overdoses, abuse, and other harms and uncertainty about long-term effectiveness. To evaluate evidence on the effectiveness and harms of long-term (>3 months) opioid therapy for chronic ...
  10. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop.

    Annals of Internal Medicine 162(4):276 (2015) PMID 25581257

    Increases in prescriptions of opioid medications for chronic pain have been accompanied by increases in opioid overdoses, abuse, and other harms and uncertainty about long-term effectiveness. To evaluate evidence on the effectiveness and harms of long-term (>3 months) opioid therapy for chronic ...
  11. Comparative effectiveness of imaging modalities to determine metastatic breast cancer treatment response.

    The Breast 24(1):3 (2015) PMID 25479913

    We performed a systematic review to address the comparative effectiveness of different imaging modalities in evaluating treatment response among metastatic breast cancer patients. We searched seven multidisciplinary electronic databases for relevant publications (January 2003-December 2013) and ...
  12. Evaluating treatments and corresponding costs of prostate cancer patients treated within an inpatient or hospital-based outpatient setting.

    Future Oncology 11(3):439 (2015) PMID 25675125

    ABSTRACT  Aim: To describe treatments and cost of care for prostate cancer (PCa) in hospital-based outpatient and inpatient settings. Hospital encounters associated with PCa (ICD-9 codes 185, 233.4) and PCa-related treatment in a hospital claims database were included. There were 211,440 encount...
  13. Comparative effectiveness of imaging modalities to determine metastatic breast cancer treatment response.

    The Breast 24(1):3 (2015) PMID 25479913

    We performed a systematic review to address the comparative effectiveness of different imaging modalities in evaluating treatment response among metastatic breast cancer patients. We searched seven multidisciplinary electronic databases for relevant publications (January 2003-December 2013) and ...
  14. Cost-effectiveness: the authors reply.

    Health Affairs 34(1):188 (2015) PMID 25561660

  15. Impact and factors associated with nighttime and early morning symptoms among patients with chronic obstructive pulmonary disease.

    International Journal of Chronic Obstructive Pu... 10:577 (2015) PMID 25844033 PMCID PMC4368031

    Patients with chronic obstructive pulmonary disease (COPD) exhibit poor sleep quality and consider morning as the worst time of day for their symptoms. While work has been done to characterize nighttime (NT) and early morning (EM) symptoms in various populations, the impact and factors associate...
  16. Health care costs among renal cancer patients using pazopanib and sunitinib.

    Journal of managed care & specialty pharmacy 21(1):37 (2015) PMID 25562771

    Pazopanib was noninferior to sunitinib in progression-free survival in a phase III, open-label, randomized clinical trial comparing the efficacy and safety of the 2 drugs for treatment of patients with advanced renal cell carcinoma (RCC). A secondary analysis of this trial conducted on patient-r...
  17. Impact and factors associated with nighttime and early morning symptoms among patients with chronic obstructive pulmonary disease.

    International Journal of Chronic Obstructive Pu... 10:577 (2015) PMID 25844033 PMCID PMC4368031

    Patients with chronic obstructive pulmonary disease (COPD) exhibit poor sleep quality and consider morning as the worst time of day for their symptoms. While work has been done to characterize nighttime (NT) and early morning (EM) symptoms in various populations, the impact and factors associate...
  18. Health care costs among renal cancer patients using pazopanib and sunitinib.

    Journal of managed care & specialty pharmacy 21(1):37 (2015) PMID 25562771

    Pazopanib was noninferior to sunitinib in progression-free survival in a phase III, open-label, randomized clinical trial comparing the efficacy and safety of the 2 drugs for treatment of patients with advanced renal cell carcinoma (RCC). A secondary analysis of this trial conducted on patient-r...
  19. Health care costs among renal cancer patients using pazopanib and sunitinib.

    Journal of managed care & specialty pharmacy 21(1):37 (2015) PMID 25562771

    Pazopanib was noninferior to sunitinib in progression-free survival in a phase III, open-label, randomized clinical trial comparing the efficacy and safety of the 2 drugs for treatment of patients with advanced renal cell carcinoma (RCC). A secondary analysis of this trial conducted on patient-r...
  20. Cost-effectiveness: the authors reply.

    Health Affairs 34(1):188 (2015) PMID 25561660